Resmed CEO Mick Farrell [Image courtesy of AdvaMed]
AdvaMed announced today that it has named Resmed Chair and CEO Michael “Mick” Farrell as the next chair of its board of directors.
He will kick off a two-year term chairing the board of the medical device industry group, starting in January 2026.
Farrell succeeds GE HealthCare CEO Peter Arduini, whose two-year term has come to an end after his announced appointment in December 2023. Arduini had succeeded Insulet CEO Ashley McEvoy, the former leader of Johnson & Johnson MedTech. McEvoy resigned from J&J in October 2023 and subsequently stepped down as AdvaMed chair less than a year into a two-year term.
“The entire board and the global industry AdvaMed represents are excited to have Mick as our chair during a rapidly evolving pace of medtech innovation,” AdvaMed President and CEO Scott Whitaker said in a news release. “Whether in international forums or in the halls of the U.S. Congress, Mick’s enthusiasm for the power of medtech to change lives is endless and contagious. His egalitarian approach is inspiring. As chairman and CEO of Resmed, he is relentlessly committed to helping people sleep better, breathe better, and live longer, healthier lives. We’ll continue to take inspiration from his vision of life-changing medtech for all.”
More about Mick Farrell
Farrell has served on AdvaMed’s board since 2015. He currently chairs the organization’s International Board Committee and recently joined a delegation to Japan focused on medtech and healthy aging.
Resmed appointed Farrell as its CEO in March 2013 and he became the company’s board chair in January 2023. He has been at Resmed in a number of leadership roles since 2000. Prior to Resmed, he spent time at Arthur D. Little, Sanofi Genzyme, Dow Chemical, and BHP. Farrell also currently serves as lead independent director on Zimmer Biomet’s board.
(Farrell recently spoke to our sister site, MassDevice, in an exclusive interview at AdvaMed’s The MedTech Conference in San Diego. Read more from him here.)
AdvaMed said Farrell will “announce more details on his priorities in early 2026.”
“I’m honored by the trust of my peers to serve as chair of AdvaMed,” Farrell said. “It’s a privilege to follow in the footsteps of leaders like Mike Minogue, Ashley McEvoy, and Pete Arduini, who each brought powerful focus to our shared goal of putting patients first, driving innovation, and shaping a better future for health care. As chair, I’ll build on that foundation. I’m focused on accelerating patient-first innovation, advancing digital transformation, and expanding global access to medtech. That means supporting policies that enable care to be delivered everywhere, from hospitals to homes, and personalizing that care for every individual. Together, we can share what’s next in health care, and I’m excited to get to work.”
More on Peter Arduini’s tenure as AdvaMed chair
In two years and some change as AdvaMed chair, Arduini’s time included key achievements like the firm establishment and integration of the group’s Imaging and Digital Health Tech divisions. This contributed to a surge in membership from 398 companies to 615, AdvaMed said.
Additionally, AdvaMed secured accreditation by the American National Standards Institute (ANSI) as a Standards Development Organization (SDO) under Aruduini. This ensures that AdvaMed may convene stakeholders across the global medtech ecosystem to create consensus-driven standards for patients, providers, regulators, and innovators worldwide.
Other key advances of his tenure include “the strongest momentum to date” on Medicare coverage for breakthrough medical technology. Additionally, AdvaMed said he oversaw “overwhelming passage of legislation” from a key congressional committee and support from top administration leaders.
Also under Arduini, AdvaMed helped secure final CMS regulations to expand access to a range of therapies for Medicare beneficiaries. Those include diagnostic radiopharmaceuticals used to diagnose illnesses including Alzheimer’s, Parkinson’s, heart disease, and certain types of cancer; computed tomography colonography (CTC), a minimally invasive colorectal cancer screening tool; a category of digital mental health treatment devices; and non-opioid treatments for pain relief.
A final regulation on ethylene oxide during Arduini’s tenure “was more workable than proposed.” This preserved the sterilization method while continuing to protect public health, AdvaMed said.
“Pete’s proven record of leadership over more than three decades in medtech and imaging were critical to AdvaMed at a pivotal period,” Whitaker said. “Under his stewardship, AdvaMed fully integrated its new imaging and digital health tech divisions, securing our position as the only trade association representing the entire medtech and health tech ecosystem, from the companies traditionally considered medtech to tech companies engaging in digital health.
“Pete set us on a clear path to achieve multiple policies necessary for patient access to next-generation medtech and health tech. We’re grateful for his service.”
link